Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TRIAD - Treatment of Insomnia and Depression

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Stanford University.
Recruitment status was:  Active, not recruiting
Duke University
University of Pittsburgh
University of Pennsylvania
Information provided by (Responsible Party):
Stanford University Identifier:
First received: October 3, 2008
Last updated: November 27, 2013
Last verified: November 2013

October 3, 2008
November 27, 2013
December 2008
April 2014   (final data collection date for primary outcome measure)
Rate of depression remission [ Designated as safety issue: No ]
Rate of depression remission
Complete list of historical versions of study NCT00767624 on Archive Site
Rate of Insomnia remission [ Designated as safety issue: No ]
Rate of Insomnia remission
Not Provided
Not Provided
TRIAD - Treatment of Insomnia and Depression
Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants
The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.
Participants with major depressive disorder and insomnia who meet all study criteria will receive state-of-the-art antidepressant medications and one of two insomnia therapies. The specific therapy for insomnia will be determined by chance (like a flip of a coin), with an equal chance to receive either cognitive-behavioral therapy for insomnia or desensitization psychotherapy for insomnia. The study physician will select an initial antidepressant medication from a list of three possible medications . If that medication is not helpful, another medication may be tried after 8 weeks or in the event of severe side effects.
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Sleep Initiation and Maintenance Disorders
  • Depression
  • Drug: Antidepressant
    Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
  • Behavioral: Desensitization Therapy for Insomnia
  • Behavioral: Cognitive Behavioral Therapy for Insomnia
  • antidepressant + desensitization
    Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
    • Drug: Antidepressant
    • Behavioral: Desensitization Therapy for Insomnia
  • antidepressant + cognitive behavioral
    Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
    • Drug: Antidepressant
    • Behavioral: Cognitive Behavioral Therapy for Insomnia
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Meets criteria for Major Depressive Disorder
  2. Between 18 and 75 years of age and adequately fluent in English
  3. Meets criteria for an insomnia disorder

Exclusion Criteria:

  1. Women who are currently pregnant, breast-feeding, or not using a reliable birth control method.
  2. People for whom the antidepressant medication(s) provided in the study is not indicated
  3. People who have had minimum adequate trials of (or have not been able to tolerate) all three study medications.
  4. People with uncontrolled medical conditions.
  5. People with moderate or severe sleep disorders other than insomnia
  6. Individuals on a fixed night shift or rotating work schedule that requires a night shift.
  7. Patients with a current principal diagnosis of a psychiatric disorder that necessitates treatment that is not offered in the study.
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
SU-08132008-1277, MH78924
Not Provided
Not Provided
Not Provided
Stanford University
Stanford University
  • Duke University
  • University of Pittsburgh
  • University of Pennsylvania
Principal Investigator: Rachel Manber Stanford University
Stanford University
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP